Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4(+) T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
In the citing paper
“The immunogenic i.m. route was chosen for these experiments, as hepatic gene transfer typically results in tolerance induction to FIX (24, 38).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Expression of DTR under XCR1 promoter allowed specific depletion of XCR1+ DCs by administration of diphtheria toxin (DT) whereas expression of fluorescent protein allowed their easy detection and tracking.”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Fortunately, the immune response is not always against AAV-mediated gene transfer, evidenced by induction of regulatory T cells (Tregs) that suppress immune response and facilitate sustained transgene expression (34, 35).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Self-citationInduction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846 · cited 7×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialRoncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814 · cited 6×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialLimmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“Liver transplants are often not rejected even across MHC barriers, and LSECs have been shown to represent specialized APCs that can induce T cell tolerance (40, 42).”
BackgroundLocal control of the immune response in the liver
Knolle, P. A., & Gerken, G. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017408.x · Cited by 603 · cited 3×
“) promotes tolerance rather than immunity to the transgene product (40).”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554 · cited 3×
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundSelf-citationAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“AAV vector (serotype 2) was produced by triple transfection of HEK-293 cells, purified by CsCl-gradient centrifugation, and quantitated by dot blot hybridization as described (23).”
MethodNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“IX as designed by Kay and colleagues (22).”
MethodJooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 5×
“Even with a ubiquitous promoter, hepatocytes are the major site of F.IX synthesis following portal infusion of AAV vector, which has a strong tropism for liver and does not appear to transduce other cell types within the liver or APCs (24, 43, 44).”
BackgroundInfluential
Research works printed but not linked: 2
- Manno, C.S., et al. 2003. A phase I safety study in patients with severe hemophilia B using adeno-associated viral (AAV) vector to deliver the gene for human factor IX to skeletal muscle. Blood . In press.
- Nakai, H., et al. 2000. A proposed rAAV-liver directed clinical trial for hemophilia B. Blood. 96 (Suppl.):798a-799a.
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Mátés, L., Chuah, M. K. L., Belay, E., Jerchow, B., Manoj, N., Acosta-Sanchez, A., Grzela, D. P., Schmitt, A., Becker, K., Matrai, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.343 · Cited by 948
“This suggests that hepatic expression of FIX following nonviral transposon-mediated gene delivery may be associated with the induction of FIX-specific immune tolerance [13].”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
“Subsequent work demonstrated that expression of a transgene from an AAV vector in the liver promotes tolerance to the transgene produc”
BackgroundSelf-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“While in preclinical settings, AAV-mediated transgene expression in the liver is reproducibly achieved using both constitutive and tissue-specific promoters; the restriction of transgene expression in hepatocytes is a preferred choice to avoid the expression of the transgene product in antigen-presenting cells (that m…”
BackgroundSelf-citationImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
Self-citationImmune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N., GarciaCozar, F. J., & Boissier, M.-C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 633
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Self-citationZhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Self-citationBrown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
“Previously, we and others have used tissue-specific promoters to target transgene expression to hepatocytes and prevent expression within APC”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“Several studies of gene transfer with rAAV in both small and large animals indicated that hepatocyterestricted transgene expression induced a robust, antigenspecific peripheral tolerance (60, 92, 93).”
BackgroundSelf-citationJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Self-citationMingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citationNiemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Self-citationNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
Self-citationInhibitor development in haemophilia B: an orphan disease in need of attention
DiMichele, D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06657.x · Cited by 251
“Immunological tolerance with hepatic gene transfer has been achieved in a haemophilia B mouse model (Mingozzi et al, 2003; Dobryznski & Herzog, 2005).”
BackgroundA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Self-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
Self-citationBreous, E., Somanathan, S., Vandenberghe, L. H., & Wilson, J. M. (2009) · Hepatology · doi:10.1002/hep.23043 · Cited by 237
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Self-citationCao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., & Herzog, R. W. (2007) · Blood · doi:10.1182/blood-2007-02-073304 · Cited by 220
“11 While our laboratory has obtained evidence for induction of CD4 T-cell anergy and deletion using ovalbumin (ova) as a model antigen in hepatic AAV-mediated gene transfer, studies with hFIX also provided evidence for induction of CD4 regulatory T cells (Tregs).(11,12) These cells were found to suppress antibody and…”
Self-citationKeenan, B. P., Fong, L., & Kelley, R. K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0749-z · Cited by 220
“Liver sinusoidal endothelial cells (LSECs) are specialized endothelial cells which sample portal venous blood and act as antigen-presenting cells (APCs) with the ability to cross-prime T cells [40, 41].”
BackgroundInfluentialVandendriessche, T., Thorrez, L., Acosta‐Sanchez, A., Petrus, I., Wang, L., Ma, L., De Waele, L., Iwasaki, Y., Gillijns, V., Wilson, J. M., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02220.x · Cited by 209
Follenzi, A., Battaglia, M., Lombardo, A., Annoni, A., Roncarolo, M. G., & Naldini, L. (2004) · Blood · doi:10.1182/blood-2003-09-3217 · Cited by 212
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Self-citationPien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
Self-citationLessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
“…a loss in efficacy regarding TG levels that was attributed to an immune response to the AAV1 capsid, as CD8 + T cell responses against the AAV capsid have previously been reported to affect transgene expression in a trial of AAV2 in the liver of patients with hemophilia B (Mingozzi et al., 2003).”
BackgroundUpdate on clinical gene therapy for hemophilia
Perrin, G. Q., Herzog, R. W., & Markusic, D. M. (2019) · Blood · doi:10.1182/blood-2018-07-820720 · Cited by 175
Self-citationImmunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Zhu, Y., Jiang, J.-L., Gumlaw, N. K., Zhang, J., Bercury, S. D., Ziegler, R. J., Lee, K., Kudo, M., Canfield, W. M., Edmunds, T., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.37 · Cited by 177
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173
“10 Inhibitor formation against FIX by this route of administration in mice is very rare, although it could happen in some strains of mice and it correlated with low FIX expression.(11) Among the hemophilia B dogs treated with AAV vectors via the liver approach, only one dog with the null mutation developed anti-cFIX a…”
BackgroundrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Franco, L. M., Sun, B., Yang, X., Bird, A., Zhang, H., Schneider, A., Brown, T., Young, S. P., Clay, T. M., Amalfitano, A., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.024 · Cited by 169
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Self-citationImmunogenicity of Protein Pharmaceuticals
Dingman, R. K., & Balu‐Iyer, S. V. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.014 · Cited by 182
Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288001 · Cited by 157
Self-citationTreatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“Interestingly, experiments in mice and dogs have yielded sustained hepatic F.IX expression in animal models that consistently showed inhibitor formation in the context of muscle-directed gene transfer (Mingozzi et al. 2003; Mount et al. 2002; Nathwani et al. 2001).”
BackgroundInfluentialSelf-citationImmunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 147
“The liver also exhibits immune tolerance through mechanisms such as suboptimal activation of cytotoxic T-cells,(201) antigen-induced inhibition of T-cells,(209) and/or activation of immunosuppressive Tregs.(199,206,208,210,211) For example, in nonhuman primates, intravenous injection of recombinant AAVs induced immune…”
BackgroundHerzog, R. W., Fields, P. A., Arruda, V. R., Brubaker, J. O., Armstrong, E., McClintock, D., Bellinger, D. A., Couto, L. B., Nichols, T. C., & High, K. A. (2002) · Human Gene Therapy · doi:10.1089/104303402760128513 · Cited by 147
Self-citationNext-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
Ziegler, R. J., Lonning, S. M., Armentano, D., Li, C., Souza, D. W., Cherry, M., Ford, C., Barbon, C. M., Desnick, R. J., Gao, G., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.015 · Cited by 141
“Similar observations were reported recently for AAV2-derived Factor IX in multiple mouse strains [22].”
BackgroundResultInfluentialRescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
Puzzo, F., Colella, P., Biferi, M. G., Bali, D., Paulk, N. K., Vidal, P., Collaud, F., Simon-Sola, M., Charles, S., Hardet, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6375 · Cited by 135
“Another key feature of targeting the GAA transgene to liver is that GAA expression in hepatocytes results in induction of immunological tolerance (24).”
BackgroundSelf-citationMátrai, J., Cantore, A., Bartholomae, C. C., Annoni, A., Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., et al. (2011) · Hepatology · doi:10.1002/hep.24230 · Cited by 139
Adeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135
Self-citationPathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX
Lollar, P. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00802.x · Cited by 135
Experimental in vitro and in vivo models for the study of human hepatitis B virus infection
Allweiss, L., & Dandri, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.012 · Cited by 143
“[104] Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, et al.”
BackgroundMarkusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
Self-citationThe Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2011) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 125
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
“Last, as suggested here by the higher frequency of Tregs found in lymph nodes of exo-AAV–treated animals, higher transgene expression levels are likely to result in more robust induction of immunological tolerance.(27) One additional potential advantage deriving from the use of highly efficient exo-AAV vectors is a de…”
BackgroundSelf-citationSabatino, D. E., Lange, A. M., Altynova, E. S., Sarkar, R., Zhou, S., Merricks, E. P., Franck, H. G., Nichols, T. C., Arruda, V. R., & Kazazian Jr, H. H. (2011) · Molecular Therapy · doi:10.1038/mt.2010.240 · Cited by 120
Self-citationImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Sun, B., Bird, A., Young, S. P., Kishnani, P. S., Chen, Y.-T., & Koeberl, D. D. (2007) · The American Journal of Human Genetics · doi:10.1086/522236 · Cited by 130
“The mechanism for achieving immune tolerance, although incompletely understood, clearly depends on the induction of regulatory T cells that repress the formation of cytotoxic T cells.(16,21,22) The LSP reduced the g-interferon response to introduced GAA expression in comparison with a universally active promoter, whic…”
InfluentialHepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P., Hoffman, B., & Herzog, R. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 114
“This unresponsiveness cannot be explained by a shift in cytokine secretion patterns or in isotype switch for antibody production, ruling out an immune deviation mechanism [76].”
BackgroundSelf-citationEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
“Published by John Wiley and Sons, Ltd on behalf of EMBO. showed anaphylactic reactions as previously published (Verma et al, 2010).”
BackgroundMethodInfluentialSelf-citationMingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Self-citationSun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., & Koeberl, D. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.012 · Cited by 111
“The mechanism for induction of tolerance to liver-targeted expression of FIX involved regulatory CD4 T cells that suppressed neutralizing antibody formation, and higher levels of FIX expression increased the likelihood of tolerance [25].”
BackgroundPre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 108
Self-citationSabatino, D. E., MacKenzie, T. C., Peranteau, W., Edmonson, S., Campagnoli, C., Liu, Y.-L., Flake, A. W., & High, K. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300219 · Cited by 108
Self-citationLiao, G., Nayak, S., Regueiro, J. R., Berger, S. B., Detre, C., Romero, X., de Waal Malefyt, R., Chatila, T. A., Herzog, R. W., & Terhorst, C. (2010) · International Immunology · doi:10.1093/intimm/dxq001 · Cited by 100
Self-citationAshe, K. M., Budman, E., Bangari, D. S., Siegel, C., Nietupski, J. B., Wang, B., Desnick, R. J., Scheule, R. K., Leonard, J. P., Cheng, S. H., et al. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00088 · Cited by 107
Dobrzynski, E., Fitzgerald, J. C., Cao, O., Mingozzi, F., Wang, L., & Herzog, R. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508685103 · Cited by 105
Self-citationSchagen, F. H. E., Ossevoort, M., Toes, R. E. M., & Hoeben, R. C. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(03)00172-0 · Cited by 119
“clotting factor IX in an murine hemophilia B model) may even induce tolerance to the therapeutic antigen [36].”
BackgroundGene therapy for hemophilia: what does the future hold?
Doshi, B. S., & Arruda, V. R. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718791933 · Cited by 97
Self-citationToromanoff, A., Chérel, Y., Guilbaud, M., Penaud-Budloo, M., Snyder, R. O., Haskins, M. E., Deschamps, J.-Y., Guigand, L., Podevin, G., Arruda, V. R., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.87 · Cited by 99
Self-citationCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
“For example, preclinical studies of intramuscular delivery of AAV vectors suggest that this approach carries a higher risk of triggering immune responses to the transgene (42) compared to other tissues such as the liver (43), and that the underlying disease-causing mutation is a major determinant of the risk of develo…”
BackgroundSelf-citationSystemic protein delivery by muscle-gene transfer is limited by a local immune response
Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., & Herzog, R. W. (2005) · Blood · doi:10.1182/blood-2004-03-0848 · Cited by 94
Self-citationChallenges and strategies: The immune responses in gene therapy
Zhou, H., Liu, D., & Liang, C. (2004) · Medicinal Research Reviews · doi:10.1002/med.20009 · Cited by 98
“The other experiment showed that the greatly reduced risk of anti-FIX formation following hepatic gene transfer with an AAV vectors is the result of FIX-specific induction of immune tolerance by this route of administration.(71) In fact, the different routes of administration determine which immune organs and cell pop…”
BackgroundMurphy, S. L., & High, K. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06942.x · Cited by 109
“In fact, AAV vector transduction in the liver can result in the induction of immune tolerance to the transgene product (Mingozzi et al, 2003).”
BackgroundSelf-citationImmune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Modulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Liu, L., Mah, C. S., & Fletcher, B. S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.021 · Cited by 102
“demonstrated that higher levels of protein expression from the liver favored tolerance induction in a hemophilia B model using AAV-mediated gene transfer [42].”
MethodMajor role of local immune responses in antibody formation to factor IX in AAV gene transfer
Wang, L., Cao, O., Swalm, B., Dobrzynski, E., Mingozzi, F., & Herzog, R. W. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302539 · Cited by 98
Self-citationAAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects
Hasbrouck, N. C., & High, K. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.71 · Cited by 100
Self-citationThe liver works as a school to educate regulatory immune cells
Li, F., & Tian, Z. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.7 · Cited by 95
Teruel-Montoya, R., Kong, X., Abraham, S., Ma, L., Kunapuli, S. P., Holinstat, M., Shaw, C. A., McKenzie, S. E., Edelstein, L. C., & Bray, P. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102259 · Cited by 90
“Even when tissue-preferential promoters are used to direct transgene expression, off-target and deleterious effects have been observed [61,62].”
Immune surveillance of the liver by T cells
Ficht, X., & Iannacone, M. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba2351 · Cited by 88
“Despite this abundance of immune cells, the liver has remarkable tolerogenic properties, exemplified by the acceptance of liver allografts across major histocompatibility complex (MHC)–mismatch barriers (10–13), the unresponsiveness toward antigens (Ags) specifically expressed in hepatocytes (14, 15), and the propensi…”
BackgroundCao, O., Hoffman, B. E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C., High, K. A., & Herzog, R. W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.159 · Cited by 92
Self-citationLiver gene therapy: advances and hurdles
Nguyen, T., & Ferry, N. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302373 · Cited by 102
Ziegler, R. J., Cherry, M., Barbon, C. M., Li, C., Bercury, S. D., Armentano, D., Desnick, R. J., & Cheng, S. H. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300066 · Cited by 89
Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9
Stephens, C. J., Lauron, E. J., Kashentseva, E. A., Lu, Z. H., Yokoyama, W. M., & Curiel, D. T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.009 · Cited by 98
“5 μg/mL) might suggest greater correction [65].”
Evading the immune response upon in vivo gene therapy with viral vectors.
Sack, B. K., & Herzog, R. W. (2009) · PubMed · Cited by 106
Self-citationZhang, P., Sun, B., Osada, T., Rodriguiz, R., Yang, X. Y., Luo, X., Kemper, A. R., Clay, T. M., & Koeberl, D. D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.063 · Cited by 88
“Acquisition of tolerance to FIX required induction of regulatory CD4 + T cells, most likely CD4 + CD25 + regulatory T (Treg) cells, which suppressed neutralizing antibody formation (Mingozzi et al. , 2003).”
InfluentialImproved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer
Cooper, M., Nayak, S., Hoffman, B. E., Terhorst, C., Cao, O., & Herzog, R. W. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.161 · Cited by 90
Self-citationImmune Responses to Lentiviral Vectors
Follenzi, A., Santambrogio, L., & Annoni, A. (2007) · Current Gene Therapy · doi:10.2174/156652307782151515 · Cited by 87
“Unfortunately, tissue-restricted expression of a transgene was only able to reduce the incidence and the extent of transgene-specific immune responses, which still can be observed at lower levels and are delayed in time [Follenzi et al., 2004; Mingozzi et al., 2003].”
BackgroundMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
Self-citationBortolussi, G., Zentillin, L., Vaníkova, J., Bockor, L., Bellarosa, C., Mancarella, A., Vianello, E., Tiribelli, C., Giacca, M., Vitek, L., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.233 · Cited by 85
“the control of the enhancer element of the ApoE gene and the minimal promoter region of the AAT gene (Mingozzi et al., 2003).”
BackgroundMethodInfluentialNair, N., Rincon, M. Y., Evens, H., Sarcar, S., Dastidar, S., Samara-Kuko, E., Ghandeharian, O., Man Viecelli, H., Thöny, B., De Bleser, P., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534032 · Cited by 84
Gene therapy for haemophilia: a long and winding road
High, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04369.x · Cited by 86
Self-citationKumar, S. R. P., Hoffman, B. E., Terhorst, C., de Jong, Y. P., & Herzog, R. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.014 · Cited by 83
“These observations are consistent with our earlier reports on induction of B cell tolerance to the transgene product when high levels of antigen expression in the liver are achieved, whereas lower levels may not protect from antibody formation.(6) Several liver-resident APCs (including liver sinusoidal endothelial cel…”
BackgroundResultSelf-citationLiver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
“In the context of gene replacement therapy, the transgene needs to be expressed above a threshold level to ensure immune tolerance induction, as expression below this threshold can induce adverse immune responses [5, 98].”
BackgroundResultEffect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
“In XCR1 mice, coding region of the Xcr1 gene was replaced with a genetic cassette encoding diphtheria toxin receptor (DTR) and reporter protein “Venus” (a yellow fluorescent protein) (24, 25).”
MethodSelf-citationLievens, J., Snoeys, J., Vekemans, K., Linthout, S. V., Zanger, R. D., Collen, D., Wisse, E., & Geest, B. D. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302326 · Cited by 83
Han, S.-O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., & Koeberl, D. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.010 · Cited by 78
“Notably, an isotype switch from IgG1 to IgG2b and IgG2c isotypes has been associated with the induction of peripheral tolerance mediated by the liver.(17)”
BackgroundSelf-citationPersistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer
Kang, Y., Xie, L., Tran, D. T., Stein, C. S., Hickey, M., Davidson, B. L., & McCray, P. B. (2005) · Blood · doi:10.1182/blood-2004-11-4358 · Cited by 76
Metadata
- Authors
- Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-01
- Volume
- 111
- Issue
- 9
- Pages
- 1347-1356
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC154443
- OpenAlex
- W4250446838
- Cited by
- 466
- References
- 44
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 17 · 2021: 16 · 2020: 19 · 2019: 21 · 2018: 24 · 2017: 29 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 17 · 2012: 23
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Hemophilia Foundation
- Hemophilia of Georgia
- National Institutes of Health (5r01hl061921-02)
- National Heart, Lung, and Blood Institute (R01 HL61921)
- National Institute of Allergy and Infectious Diseases (R01 AI/HL 51390-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune tolerance, coagulation factor IX, AAV gene delivery, hepatic gene transfer, gene replacement therapy, hemophilia B, regulatory T cells, T cell tolerance, transgene expression, secreted antigens, humoral immune response
- MeSH terms
- Dependovirus, Animals, Antibodies, Hemophilia B, Factor IX, Humans, Immune Tolerance, Liver, Mice, Inbred Strains, Promoter Regions, Genetic, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Interleukin-4, Gene Transfer Techniques, Mice, Knockout, fas Receptor, Adoptive Transfer, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.